Predicting recurrence of Stage IA lung adenocarcinoma using ctDNA whole genome mutational signatures.

Matija Snuderl¹, James Smadbeck², Reid Wilkins³, Kenneth Tokoro⁴, Ryan Ptashkin², Isabella Pizzillo³, Alejandro Vargas³, Andre Moreira³, Danielle Afterman⁵, Tomer Lauterman⁵, Maja Kuzman², Santiago Gonzalez², Dunja Glavas², Dillon Maloney², Jurica Levatic², Samuel Phillips², Sunil Deochand², Michael Yahalom⁵, Iman Tavassoly⁵, Zohar Donenhirsh⁵, Eric White², Ravi Kandasamy², Ury Alon⁵, Paz Polak², Boris Oklander⁵, Asaf Zviran², Harvey I Pass⁶

¹Department of Pathology, NYU Langone Health and Grossman School of Medicine, New York, New York,; Laura and Isaac Perlmutter Cancer Center, New York, New York. Electronic address: Matija.Snuderl@nyulangone.org.

²C2i Genomics Inc., New York, New York.

³Department of Pathology, NYU Langone Health and Grossman School of Medicine, New York, New York.

⁴Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York.

⁵C2i Genomics Inc., Haifa, Israel.

⁶Department of Cardiothoracic Surgery, NYU Langone Health, New York, New York,. Electronic address: Harvey.Pass@nyulangone.org.

PubMed DOI

Abstract

Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality. While for Stage IA LUAD surgery is often curative, recurrence rates remain significant. Liquid biopsy enables monitoring residual disease and predicts recurrence, however utility in Stage IA LUAD is not well-established. Tumor-informed whole genome sequencing (WGS) represents a highly sensitive liquid biopsy method for…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.